MiMedx to Acquire Sanara MedTech for $350M, Expanding Surgical Footprint and Projecting Accretion
MDXG sits 38% above its 52-week low of $3.025.
Summary
MiMedx Group, Inc. announced a definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash and stock transaction, significantly expanding its surgical market presence and expecting immediate financial accretion.
Key Events · M&A and Partnerships · MDXG
-
Acquisition Agreement
MiMedx will acquire Sanara MedTech for approximately $350 million. Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MiMedx common stock (valued at $2.00) for each Sanara share, totaling $35.00 per share.
-
Strategic Expansion
The acquisition is expected to nearly double MiMedx's surgical revenue, creating a more diversified surgical technology platform and expanding its reach into musculoskeletal applications.
-
Financial Impact
The transaction is anticipated to be immediately accretive to MiMedx's revenue growth, gross margin, and Adjusted EBITDA margin, with over $20 million in run-rate cost synergies expected in 2027. Combined 2027 total revenue is projected to be well in excess of $400 million with an Adjusted EBITDA margin over 20%.
-
Financing Details
The cash portion of the acquisition will be funded through cash on hand and a new $300 million senior secured term loan from Hayfin Capital Management, LLP. MiMedx expects to issue 4.4 million shares for the stock consideration.
Analysis · MDXG · Industrial Applications And Services
This is a highly significant strategic move for MiMedx, as the acquisition of Sanara MedTech for $350 million represents a substantial expansion of its surgical business, nearly doubling its surgical revenue. The deal is structured to be immediately accretive to key financial metrics, including revenue growth, gross margin, and Adjusted EBITDA margin, supported by over $20 million in anticipated cost synergies. The financing, a combination of cash and a new $300 million term loan, along with the issuance of 4.4 million shares, indicates a well-planned integration aimed at strengthening MiMedx's position in the regenerative medicine market.
At the time of this filing, MDXG was trading at $4.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.